Sight Sciences, Inc. (SGHT)

US — Healthcare Sector
Peers: SIBN  RPID  TCMD  LUNG  AORT  ANIK  OFIX  AVNS  FNA  VREX  KIDS  NPCE  CVRX  NUVA  CNMD 

Automate Your Wheel Strategy on SGHT

With Tiblio's Option Bot, you can configure your own wheel strategy including SGHT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SGHT
  • Rev/Share 1.5229
  • Book/Share 1.5135
  • PB 2.3257
  • Debt/Equity 0.0
  • CurrentRatio 10.4691
  • ROIC -0.4247

 

  • MktCap 181991392.0
  • FreeCF/Share -0.4765
  • PFCF -7.4471
  • PE -3.6551
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.5462

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SGHT UBS -- Buy -- $5.5 Dec. 6, 2024
Initiation SGHT Lake Street -- Buy -- $10 Aug. 21, 2024

News

About Sight Sciences, Inc. (SGHT)

  • IPO Date 2021-07-15
  • Website https://www.sightsciences.com
  • Industry Medical - Devices
  • CEO Mr. Paul Badawi
  • Employees 216

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.